Necrosis News and Research

RSS

Incidence and severity emerging CVD risk factors may differ between genders

The incidence and severity of both traditional and emerging cardiovascular disease (CVD) risk factors as well as the response to treatment may differ between genders. In this narrative review, several emerging CVD risk factors (i.e. inflammatory and haemostatic markers, endothelial dysfunction, homocysteine, lipid disorders, microalbuminuria/proteinuria, coronary artery calcium score, arterial stiffness, periodontitis, inflammatory bowel syndrome, obstructive sleep apnea, impaired glucose metabolism, metabolic syndrome and non-alcoholic fatty liver disease) are discussed in the context of gender differences.

5 Feb 2016

Duke researchers identify promising target for renal cell carcinomas

All cells need nutrients, but cancer cells are notoriously power hungry. As a result, cancer cells must alter their metabolism to provide the additional fuel needed for them to survive, grow and spread.

4 Feb 2016

Scientists trace one of the causes of ischemia renal failure

Every year acute renal failure affects over 13 million people and leads to 1.7 million deaths across the globe. It often develops when an insufficient supply of oxygen reaches the kidneys, a condition called ischemia.

29 Jan 2016

LMU researchers reveal how crystalline deposits induce cell death

Crystal formation plays a defining role in the pathogenesis of a range of common diseases, such as gout and atherosclerosis. Ludwig-Maximilians-Universitaet (LMU) in Munich researchers led by Hans-Joachim Anders have now elucidated how the insoluble deposits induce cell death.

29 Jan 2016

New study shows bone marrow lesions could help identify rapidly progressing osteoarthritis

A new study from the Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, shows lesions, which can best be seen on MRI scans, could help identify individuals who are more likely to suffer from more rapidly progressing osteoarthritis.

18 Jan 2016

Cornell researchers identify potent cancer-killing proteins that can kill tumors in bloodstream

Cornell researchers have discovered potent cancer-killing proteins that can travel by white blood cells to kill tumors in the bloodstream of mice with metastatic prostate cancer. The breakthrough study will be published Feb. 10 as the cover article in the Journal of Controlled Release.

13 Jan 2016

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

SillaJen, Inc., a private, clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, has announced the initiation of a multinational randomized Phase 3 open-label study of its lead product candidate, Pexa-Vec (formerly JX-594), in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC).

5 Jan 2016

E-cigarettes damage cells in ways that could lead to cancer

Adding to growing evidence on the possible health risks of electronic cigarettes, a lab team at the Veterans Affairs San Diego Healthcare System tested two products and found they damaged cells in ways that could lead to cancer. The damage occurred even with nicotine-free versions of the products.

29 Dec 2015

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.

24 Dec 2015

Study may help guide patients and physicians to determine appropriate treatment option for early breast cancer

In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age. It was also the most expensive treatment option in a younger patient population, according to a new study from The University of Texas MD Anderson Cancer Center.

11 Dec 2015

Morgan brings industry-leading ceramics to HIFU transducers

Morgan Advanced Materials, widely acknowledged as a global leader in ceramics and other advanced materials, has announced that it now has the capability to design and manufacture components for use in high intensity focused ultrasound (HIFU) technologies, particularly in medical applications.

10 Dec 2015

Patients suffering from diabetic foot have significantly impaired cognitive function

In a first-time study, Ben-Gurion University of the Negev researchers revealed a new finding in people with diabetes who suffer from "diabetic foot." Patients with this condition also have significantly impaired cognitive function.

8 Dec 2015

Research reveals genetic variants linked to treatment-related complications in children with blood diseases

Research to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition reveals genetic variants that are associated with disease severity and treatment-related complications in children with blood diseases.

7 Dec 2015

EKF biomarker identifies likely development of Diabetic Nephropathy

EKF, announces new data presented in support of soluble Tumour Necrosis Factor Receptor 1 as a biomarker to predict progression of Diabetic Nephropathy.

From EKF Diagnostics 2 Dec 2015

Could statins treat muscular dystrophy? An interview with Dr. Nick Whitehead and Dr Stan Froehner

In addition to their well established cholesterol lowering benefits, statins also have potent anti-inflammatory, anti-fibrotic and antioxidant effects, which continue to be identified in a wide range of diseases.

30 Nov 2015

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

Novartis announced today that the European Commission has approved Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS, this is the first new treatment advance in 16 years since the development of the current standard of care, anti-tumor necrosis factor (anti-TNF) therapy.

25 Nov 2015

High-fat diet appears to prompt immune cells to start consuming connections between neurons

When a high-fat diet causes us to become obese, it also appears to prompt normally bustling immune cells in our brain to become sedentary and start consuming the connections between our neurons, scientists say.

24 Nov 2015

Pathophysiological biomarkers predict PAH prognosis

Researchers have identified three biomarkers that signify an increased risk of death or requirement for lung transplantation in patients with pulmonary arterial hypertension.

13 Nov 2015

Cornell biomedical engineers develop 'super natural killer cells' to destroy cancer cells in lymph nodes

Cornell biomedical engineers have developed specialized white blood cells - dubbed "super natural killer cells" - that seek out cancer cells in lymph nodes with only one purpose: destroy them.

13 Nov 2015

No progression in joint damage in 84% of psoriatic arthritis patients

Novartis announced today new results for Cosentyx® (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic arthritis (PsA). In addition, Cosentyx maintained a treatment response in joint and skin disease, physical function and quality of life in patients over two years of treatment. These results from the extension phase of the FUTURE 1 study were presented at the 2015 Annual Meeting of the American College of Rheumatology (ACR) in San Francisco, United States.

9 Nov 2015

Necrosis News and Research

Incidence and severity emerging CVD risk factors may differ between genders

Duke researchers identify promising target for renal cell carcinomas

Scientists trace one of the causes of ischemia renal failure

LMU researchers reveal how crystalline deposits induce cell death

New study shows bone marrow lesions could help identify rapidly progressing osteoarthritis

Cornell researchers identify potent cancer-killing proteins that can kill tumors in bloodstream

SillaJen reports initiation of multinational randomized Phase 3 study of Pexa-Vec in HCC patients

E-cigarettes damage cells in ways that could lead to cancer

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Study may help guide patients and physicians to determine appropriate treatment option for early breast cancer

Morgan brings industry-leading ceramics to HIFU transducers

Patients suffering from diabetic foot have significantly impaired cognitive function

Research reveals genetic variants linked to treatment-related complications in children with blood diseases

EKF biomarker identifies likely development of Diabetic Nephropathy

Could statins treat muscular dystrophy? An interview with Dr. Nick Whitehead and Dr Stan Froehner

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

High-fat diet appears to prompt immune cells to start consuming connections between neurons

Pathophysiological biomarkers predict PAH prognosis

Cornell biomedical engineers develop 'super natural killer cells' to destroy cancer cells in lymph nodes

No progression in joint damage in 84% of psoriatic arthritis patients

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News